HBM7008 -Study on Subjects With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Study to evaluate the safety and tolerability of the study drug HBM7008, to determine the
maximum tolerated dose and/or recommended Phase 2 study dose of HBM7008.